TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes

João Vinagre1,2,3,*, Joana Nabais4,*, Jorge Pinheiro5,*, Rui Batista1,2, Rui Caetano Oliveira6, António Pedro Gonçalves1,2, Ana Pestana1,2, Marta Reis1,2, Bárbara Mesquita1,2, Vasco Pinto1,2, Joana Lyra1,2, Maria Augusta Cipriano6, Miguel Godinho Ferreira4, José Manuel Lopes1,2,5,7, Manuel Sobrinho-Simões1,2,5,7 & Paula Soares1,2,7

One of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of telomeres (ALT) mechanism. It was our objective to study if TERTp mutations were present in pancreatic endocrine tumors (PET) and could represent an alternative mechanism to ALT. TERTp mutations were detected in 7% of the cases studied and were mainly associated to patients harbouring hereditary syndromes. In vitro, using PET-derived cell lines and by luciferase reporter assay, these mutations confer a 2 to 4-fold increase in telomerase transcription activity. These novel alterations are able to recruit ETS transcription factor members, in particular GABP-α and ETV1, to the newly generated binding sites. We report for the first time TERTp mutations in PETs and PET-derived cell lines. Additionally, our data indicate that these mutations serve as an alternative mechanism and in an exclusive manner to ALT, in particular in patients with hereditary syndromes.

Normal somatic cells hold a limited life span due to the cell divisions they are allowed1. Steps towards immortalization must include deceiving the intrinsic control mechanisms that monitor telomere size. To overcome this barrier, cells must either reactivate/re-express telomerase or rely on an alternative lengthening of telomeres (ALT) mechanism. Reactivation or re-expression of telomerase is thought to be present in up to 90% of human cancers and it is generally acknowledge that proliferative cancer cells maintain their telomere length2. The remaining 10% to 15% of human cancers do not have detectable telomerase activity and a subset of such cases maintain telomere length relying on ALT. In sporadic PETs, at variance with the majority of other human cancers, ALT is recognized as the major mechanism for telomere elongation and mainly as a consequence of mutations in ATRX and DAXX genes3–5. Mutations in these genes are tightly associated with loss of expression of the respective proteins by immunohistochemistry and show a nearly perfect correlation with ALT phenotype6,7. Recently, two studies reported TERTp mutations in melanoma8,9. The initial proposed theoretical model of TERTp alterations presumed that the mutations lead to the creation of novel binding sites, with a consensus sequence 5′-CCCCTTCCGGG-3′, that generates a novel binding site for ETS transcription factors8,9. We and others reported the presence of these
recent recurrent somatic mutations in a variety of human cancers and with different prevalences. Although the major mechanism for telomere maintenance in PETs is ALT, TERTp mutations could represent an alternative mechanism so far not described in such tumors. If so, PETs might behave similarly to what is observed in central nervous system tumors, mainly in glioblastomas, where TERTp and ATRX mutations are mutually exclusive, suggesting that both genetic mechanisms can confer equivalent advantages. Considering this possibility, we decided to search for the occurrence of TERTp mutations in a large series of PETs (n = 55) and three PET cell lines.

Results

TERTp mutations, a novel contributor for PETs genetics, were mainly present in cases associated with hereditary syndromes. We detected TERTp mutations in four patients (7%), three females and one male. The association of TERTp mutation status and clinicopathological features is presented in Table 1. Three of the four (75%) TERTp mutated cases occurred in the setting of hereditary syndromes: two patients with multiple endocrine type 1 (MEN1) syndrome and a patient with Von Hippel-Lindau (VHL) syndrome (Table 2). Regarding the PET cell lines, one of the three (33%), QGP1, harboured a TERTp mutation. The mutations detected in the four PETs and in the cell line were the −124:G>A alteration.

TERTp mutations lead to augmented telomerase transcriptional activity in PETs-derived cell lines. Subsequent to the detection of TERTp mutation in PETs we investigated whether TERTp mutations are functional, in vitro, in PET-derived cell lines. By luciferase reporter assay, in comparison to the wild-type TERTp,
both mutations (−124:G > A and −146:G > A) conferred an approximately 2–4 fold increased transcriptional activity in three distinct PET-derived cell lines (Fig. 2A).

Table 2. Clinicopathological and molecular relevant data of the patients with PETs harboring TERT promoter mutations. 1 years; 2 mm; 3 according to ENETS classification; 4 according to UICC/AJCC classification; 5 months; 6 No MEN1 or VHL mutations were detected. AWD – alive without disease; DOD – death of disease; DOC – death of other causes. Clinical presentations: Case 1: Primary hyperparathyroidism and insulinoma. Known family history, both the father and a sister with pancreatic tumour, a pituitary adenoma with prolactin production and primary hyperparathyroidism; Case 3: Recurrent episodes of hypoglycaemia, associated with insulinoma. No other crises following surgery. Posterior history of recurrent upper gastrointestinal haemorrhage associated with gastric ulcers. The presence of gastrinoma has never been confirmed. In both MEN1 cases there was no clinical or laboratorial evidence of other functioning-type NET. Case 4: bilateral retinal angiomatosis, cervical spinal hemangioblastoma, endolymphatic sac tumour, hepatic haemangioma and multiple renal cysts.

Figure 1. Tel-FISH in PETs. Cases depicted in panels A–C were selected due to loss of expression of ATRX and DAXX as a surrogate marker of ALT positivity; these cases presented large, ultrabright and unbalanced size telomere FISH signals (marked by the arrows), a phenotype indicative of ALT. Panels D–F, represent TERTp mutated cases 1, 3 and 4, respectively. In these cases, although some robust telomeres were present, we did not detect ultra-bright foci and the telomeres were balanced in size. One of the TERTp mutated cases was excluded from this analysis (case 2) for technical reasons, since no Tel-FISH signal was detected.
ETS family members’ transcription factors are fundamental for transcriptional activation in PETs-derived cell lines. Using JASPAR transcription factor binding profile open-access database (http://jaspardev.genereg.net/) we found that ETV1 and GABP-α were also attractive candidates since they also respond to similar consensus sequences (Supplementary Figure 2A). Following this, we took advantage of ChIP technique to test if the antibody-immunoprecipitated chromatin contained sequences of telomerase promoter. In a qualitative analysis by conventional PCR we obtained a confirmation for the presence of TERTp sequences (Supplementary Figure 2A); in order to quantify these sequences, we performed RT-PCR of the immunoprecipitates (Fig. 2B). We observed that in QGP1 (TERTp mutated) cell line, significant higher amounts of ETS-members’ transcription factors were present in comparison to BON and CM cell lines (TERTp wild-type). Additionally, to ELK1 and ELK4, we detected that GABP-α and ETV1, with the ability to bind to TERTp regions. The results are an average of at least three independent experiments. Significance levels: P < 0.0001, ****; 0.0001 < P < 0.001, ***; 0.001 < P < 0.01, **; 0.01 < P < 0.05; and P ≥ 0.05, *; and not significant (ns). Values are mean ± SEM.

**Figure 2. In vitro TERTp functional assays in the cell lines BON, CM and QGP1.** (A) Normalized fold change in the reporter assays activity for the vectors mock, wild-type TERTp, −124 and −146 TERTp mutated vectors; Even though we only detected the −124 mutation in our samples, we also created a reporter for −146 mutation, the second most frequent alteration in other human cancers; (B) Quantitative analysis by RT-PCR of the ChIP revealed that QGP1 (TERTp mutated) cell line, presents significant higher amount of ETS transcription factors in comparison to BON and CM cell lines (TERTp wild-type). Additionally, to ELK1 and ELK4, we detected that GABP-α and ETV1, with the ability to bind to TERTp regions. The results are an average of at least three independent experiments. Significance levels: P < 0.0001, ****; 0.0001 < P < 0.001, ***; 0.001 < P < 0.01, **; 0.01 < P < 0.05; and P ≥ 0.05, *; and not significant (ns). Values are mean ± SEM.

ETS family members’ transcription factors are fundamental for transcriptional activation in PETs-derived cell lines. Using JASPAR transcription factor binding profile open-access database (http://jaspardev.genereg.net/) we found that ETV1 and GABP-α were also attractive candidates since they also respond to similar consensus sequences (Supplementary Figure 2A). Following this, we took advantage of ChIP technique to test if the antibody-immunoprecipitated chromatin contained sequences of telomerase promoter. In a qualitative analysis by conventional PCR we obtained a confirmation for the presence of TERTp sequences (Supplementary Figure 2A); in order to quantify these sequences, we performed RT-PCR of the immunoprecipitates (Fig. 2B). We observed that in QGP1 (TERTp mutated) cell line, significant higher amounts of ETS-members’ transcription factors were present in comparison to BON and CM cell lines (TERTp wild-type) (Fig. 2B). Besides ELK1 and ELK4, we also detected GABP-α and ETV1, thus indicating that these transcription factors have the ability to bind to TERTp regions in PETs-derived cell lines (Fig. 2B). Finally, by EMSA with stringent probes, that avoid the native ETS in the TERTp, designed for wild-type and −124 mutated promoter sequences, we observed the presence of a shift which was only detected with the probe containing the −124 mutated sequence in the different cell lines (Supplementary Figure 2B).

Telomere maintenance in PETs-derived cell lines. The data obtained in QGP1 experiments supported the assumption that TERTp mutations are functional and can be an alternative to ALT mechanism. So, we decided to see whether or not the cell lines recapitulate the findings in PETs. At cell level, ALT phenotype is identified by the presence of ALT-associated Promyelocytic Leukemia (PML) protein nuclear bodies that contain large amounts of telomeric DNA. In Fig. 3, we observe that the positive control for ALT, U2OS cell line and CM present significantly more co-localized telomeric DNA with PML than QGP1 cell line. Furthermore, when we counted the nuclei for the presence of co-localization of Tel-FISH/PML (Supplementary Figure 3) we observed very distinctive patterns in CM and QGP cell lines. These findings indicate that QGP1 portrays an ALT negative phenotype whereas CM is ALT positive.

Discussion
PETs had already been investigated for the presence of TERTp mutations and none were detected; however, the search was only performed in sporadic PETs. In sporadic tumors ATRX/DAXX defects that result in ALT phenotype are present in 43–45% of the cases. In contrast to this, the aforementioned ALT phenotype dropped to 6% in a subset of PETs from MEN1 syndrome patients, thus leaving space for other putative mechanisms. None of the 4 cases of our series with TERTp mutations revealed loss of expression for ATRX or DAXX, a strong
indication that in these tumors ATRX/DAXX genes do not seem to have mutations concomitantly with the TERTp alteration. Ideally, it would be necessary to genotype the ATRX and DAXX genes; however, due to the large transcript size of both genes and the absence of frozen tissue, it was not possible to follow this strategy. Furthermore, several studies have demonstrated a high correlation between the presence of mutation of ATRX/DAXX and loss of expression of the respective proteins3–6 thus allowing us to use protein expression as a surrogate marker for mutation presence. The detection of ATRX and DAXX proteins, excluding mutations in these genes, is also in agreement with the lack of ALT phenotype detection as observed in the Tel-FISH analysis. Altogether, these results fit with previous findings highlighting a duality of the genetic background in sporadic and hereditary PETs3,4,6,22 and present for the first time TERTp mutations as an alternative mechanism in PETs. Our results support also the assumption that TERTp mutations may play a role in hereditary PETs and that TERTp mutations and ALT are mutually exclusive, a feature observed also in central nervous system tumors14. In vitro, TERTp mutations by luciferase reporter assay in the cell lines BON, CM and QGP1 presented a 2–4 fold increased, a value consistent with previous reports8,9. Even though we only detected the −124 mutation in our samples, we created a reporter for −146 mutation, the second most frequent alteration in other human cancers, that also presented increased transcription although with less activity than the −124 mutation. Until recently, ELK1 and ELK4 were pointed as the main transcription factors that would bind to the newly created binding consensus induced by the mutations. Additionally, we studied GABP-α because: Bell et al. reported GABP-α to be an important transcription factor being able to recruit proximal ETS motifs24; Stern et al. demonstrated that TERTp mutation presents a mark of active chromatin and recruit GABP-α25; and Makowski et al. revealed that the recruitment of GABP-α is enable by the spatial architecture of native and the newly generated motifs in the TERTp region26. Overall, GABP-α allows the potentiation of TERTp activation24–26. Contrarily to

**Figure 3.** PML immunofluorescence combined with Tel-FISH in U2OS, CM and QGP cell lines. U2OS cell line represents a universal positive control for ALT mechanism. CM cell line, a TERTp wild-type cell line, presented a high co-localization of telomeric DNA with PML exhibiting an ALT positive phenotype. QGP1, the TERTp mutated cell line does not present frequent co-localization of telomeric DNA with being ALT negative. These findings recapitulate the observations in our series of PETs.
GAB-α, ETV1 results are more difficult to interpret at this moment. Finally, we observed that cell lines recapitulate the findings in PETs; the cell line QGP1 harbouring a TERTp mutations did not present an ALT phenotype once again pointing out TERTp mutations as an alternative mechanism and in an exclusive manner. The finding that QGP1 is ALT negative concurs with novel data obtained by whole-exome sequencing that revealed that this cell line does not have mutations in ATRX and DAXX.

Overall, we report for the first time TERTp mutations in PETs and PET’s-derived cell lines. TERTp mutations are noticeably prevalent in PET cases with a hereditary component. Our data indicates that TERTp mutations are functional and serves as an alternative and mutually exclusive mechanism to ALT in hereditary PETs. Previous studies reported that the prevalence of ATRX/DAXX defects were “late” events, associated with higher stage tumors and increased size. The suggestion that ATRX/DAXX defects leading to ALT occurs only in a later stage is compatible with the fact that in hereditary-associated tumors there is an anticipation in the manifestation of the neoplasia. Therefore, TERTp mutations could provide the additional growth advantage that would allow the growth beyond the microadenoma size without the need for ALT. Further studies are still necessary to clarify the role played by the different mechanisms for telomere maintenance in sporadic and hereditary PETs.

Methods
Tissues, patient characteristics, and follow-up data. Formalin-fixed and paraffin-embedded (FFPE) tumors were retrieved from the Pathology departments of Centro Hospitalar São João and Centro Hospitalar e Universitário de Coimbra. Clinical and follow-up data were obtained by contacting the patients’ general practitioners and in-hospital registries databases. All the tumors were re-evaluated and classified according to the ENETS and the UICC/AJCC guidelines by the same pathologist (JML). A total of 55 pancreatic endocrine tumors (PETs) of 33 female patients and 22 male patients, with a mean age of 54 years (range 14–75 years) were studied. Two patients were submitted to surgical open biopsy and neoadjuvant therapy, 15 underwent enucleation, 14 were submitted to cephalic pancreaticoduodenectomy and 24 to distal pancreatectomy. The mean size of the tumors was 33 mm (range 5–100 mm); 23 tumors were located in the head, 9 in the body, 22 in the tail of the pancreas and 1 was of uncertain location. Three out 55 cases were confirmed to present a hereditary syndrome association. The majority (96%) were well-differentiated endocrine tumors, and 67% were NET G1, with less than 2 mitoses per 10 power-fields and a Ki67 index below 2%. Extrapancreatic extension was observed in 33% of the tumors; 35% had nodal metastases; 11% had evidence of distant metastases at the time of the diagnosis. Follow-up data were obtained from 49 patients, with a mean follow up time of 61 months (range 1–182 months). Relapse or disease progression was observed in 20% patients (n = 10) with a disease-related death rate of 8% (n = 4). All the procedures described in this study were in accordance with national and institutional ethical standards. According to Portuguese law, informed consent is not required for retrospective studies.

Cell lines. The PET cell lines used in this study corresponded to BON, CM, QGP1 and U2OS. The BON-1 cell line was cultured in 1:1 mixture of DMEM and F-12 glutamax mediums (Gibco, Massachusetts, USA). The CM and QGP1 were cultured in RPMI glutamax (Gibco). The U2OS was cultured in DMEM medium (Gibco). All the mediums were prepared with 10% fetal bovine serum (Gibco), 1% PenStrep (Gibco) and 0.5% Fungizone (Gibco).

DNA extraction, PCR amplification and genotyping. DNA from FFPE tissues was retrieved from 10 um cuts after careful microdissection. DNA from cell lines was obtained from cell pellets. DNA extraction from FFPE and cell lines was performed using the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhausen, Germany) following the manufacturer’s instructions. To screen TERTp mutations, we analyzed the region containing the −124 and −146 hotspots by PCR and followed by Sanger sequencing. TERTp mutation analysis was performed with the pair of primers: Fw: 5′-CAAGGGCTGGCTGAACCTC-3′ and Rv: 5′-GTCCTGCCCCTT CACCTT-3′. Amplification of genomic DNA (25–100 ng) was performed by PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany) and according to the manufacturer’s instructions with Q solution (Qiagen). Sequencing reaction was performed with the ABI Prism BigDye Terminator Kit (Perkin-Elmer, California, USA) and the fragments were run in an ABI prism 3100 Genetic Analyzer (Perkin-Elmer). The sequencing reaction was performed in a forward direction, and an independent PCR amplification/sequencing, both in a forward and reverse direction, was performed in positive samples or samples that were inconclusive in the first amplification.

ATRX and DAXX immunohistochemistry (IHC). IHC for ATRX and DAXX was performed in representative tumor tissue sections previously selected by a Pathologist. Deparaffinized and rehydrated sections were subjected to antigen retrieval treatment in a pressure cooker in 10 mM sodium citrate buffer pH 6.0 for 5 minutes. The sections were incubated one hour in a humidified chamber with the primary antibodies ATRX (1:350, HPA001906) and DAXX (1:75, HPA008736) both from Sigma-Aldrich (Missouri, USA). Following the secondary antibody, the detection was obtained with a labelled streptavidin–biotin immunoperoxidase detection system (Thermo Scientific/Lab Vision, Fremont, USA) and the immunohistochemical staining was developed with 3,3'-diaminobenzidine substrate. Omission of the primary antibody incubation was used as negative control. Previously tested samples of normal pancreas were used as positive control.

Telomere Fluorescence In Situ Hybridization (Tel-FISH). FFPE sections were incubated in Histoclear II (National Diagnostics, USA), 100% (twice) at room temperature and 100% ethanol at −20°C, for 10 minutes. Whole tissue slides were air-dried for a minimum of 30 minutes. For cultured cells, following fixation we performed an incubation 1:100 of the PML antibody (PG-M3, Santa Cruz Biotechnology). Subsequent incubation with the secondary antibody, cells were washed with PBS, three times 10 minutes. Cells were then fixed in 10% formalin for 20 minutes in the dark followed by two washes for 5 minutes in 0.05% Tween-20 in PBS. Cells were air-dried for a minimum of 30 minutes. Cells and FFPE tissue sections were denatured for 10 min in an oven (Memmert
Luciferase Promoter Reporter Assay. Briefly, a wild-type TERTp region comprising the genomic area from −290 to the −47 bps from the initial codon was amplified by PCR using the thyroid cell line XTC-1 as the DNA template. The PCR product was then cloned into pGEM-T Easy vector (Promega, Wisconsin, USA). The plasmid generated was then digested with XhoI and KpnI enzymes (Fermentas, Massachusetts, USA) and the obtained insert was subcloned into the pGL3 luciferase expression vector (Promega), creating the TERTp wild type vector. Site directed mutagenesis was performed with QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, California, USA) and was used to generate the mutations (−124 and −146 G > A) from the wild type promoter. The final vectors, pGL3−TERTp wt, −124 and −146, were generated as reporter constructs containing the firefly luciferase-encoding gene under the control of the wild type, −124 and −146 TERTp DNA motifs, respectively. Primers are available upon request. For the luciferase promoter assay, BON, CM and QGP1 cell lines were grown to 80% confluence and transfected with 1 μg of the previously generated vectors (pGL3−wt, −124 and −146). Additionally, for normalization purposes, cells were co-transfected with 0.125 μg of pRL vector, Renilla luciferase. The transfection was performed with Lipofectamine 2000 (Life Technologies, Massachusetts, USA) in 12-well plates and accordingly to the manufacturer instructions. After 48 hours, the transfected cells were washed in a saline solution and stored at −80 °C for cell lysis. The remaining part of the assay was performed with the steadylite plus reporter gene assay system (PerkinElmer) and in accordance with the manufacturer instructions. Finally, the light counts from luciferase and renilla were obtained in a MicroBeta TriLux 1450 bioluminescence counter (PerkinElmer).

Chromatin immunoprecipitation (ChIP) assay and Real Time PCR (RT-PCR). ChIP experiments were performed using the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signalling Technology, Massachusetts, USA) according to the instructions provided by the manufacturer. Briefly, BON, CM and QGP1 cells were grown until 90% confluence was reached and DNA-protein crosslinking was achieved by adding 1% formaldehyde directly in the culture medium. Digestion and isolation of the nuclei was accomplished after incubating the samples with 5 μl of micrococcal nuclease for 20 minutes at 37°C. The quality of the chromatin preparations was assessed by electrophoresis in an agarose gel and only samples showing a pattern of chromatin fragments ranging 100–1000 bps were used in the following steps: up to 5 μg of chromatin preparation was immunoprecipitated using 1 to 2 μg of the indicated antibodies and protein G magnetic beads. DNA was then eluted from the antibody/protein G beads, purified using spin columns and used as a template for PCR and RT-PCR experiments. PCR evaluation of eluted products was performed with the conditions described above. RT-PCR employed a Sybr Green Master Mix (KAPA Biosystems Massachusetts, USA) in 20 μl reactions using the following program: 1 cycle of 60 minutes at 22°C, 1 cycle of 5 minutes at 95°C, 20 cycles of 1 minute beginning at 95°C followed by a 1°C decrease per cycle, 1 cycle of 30 minutes at 75°C and 40 cycles of 1 minute beginning at 75°C followed by a 1°C decrease per cycle. EMSA binding reactions were incubated at 22°C, 1 cycle of 5 minutes at 95°C, 20 cycles of 1 minute beginning at 95°C followed by a 1°C decrease per cycle, 1 cycle of 30 minutes at 75°C and 40 cycles of 1 min beginning at 75°C followed by a 1°C decrease per cycle. EMSA binding reactions were incubated at 22°C, 1 cycle of 5 minutes at 95°C, 20 cycles of 1 minute beginning at 95°C followed by a 1°C decrease per cycle, 1 cycle of 30 minutes at 75°C and 40 cycles of 1 min beginning at 75°C followed by a 1°C decrease per cycle. EMSA binding reactions were incubated in H2O containing the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) and consisted of 1x binding buffer, 1 μg/μl poly (dl,dC), 2.5% glycerol, 0.05% NP-40, 100 mM KCl, 2.5 mM MgCl2, 1 mM EDTA, 5 μg of protein nuclear extract and 20 fmol of biotin-labelled oligonucleotide (when indicated, 4000 fmol unlabelled oligonucleotide was also added as a competitive negative control). Binding reactions were incubated for 30 minutes at room temperature after which loading buffer was added. Samples were run on a 6% non-denaturing polyacrylamide gel, transferred to a nylon membrane and cross-linked in a UV chamber for 15 minutes. The membrane was developed in X-ray film using the Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) according to the instructions provided by the manufacturer.

Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts of BON, CM AND QGP1 cells were obtained using the NE–PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Scientific, Massachusetts, USA), according to the instructions provided by the manufacturer, and the concentration of protein quantified using Bradford's modified protein assay (Bio-Rad, California, USA). DNA oligonucleotides corresponding to the −124 and −146 regions of the TERTp were synthesized and labelled with biotin using the Biotin 3’ End DNA Labelling Kit (Thermo Scientific). The probes sequences are available upon request. The complementary oligonucleotides were annealed using a thermocycler and the following program: 1 cycle of 60 minutes at 22°C, 1 cycle of 5 minutes at 95°C, 20 cycles of 1 minute beginning at 95°C followed by a 1°C decrease per cycle, 1 cycle of 30 minutes at 75°C and 40 cycles of 1 minute beginning at 75°C followed by a 1°C decrease per cycle. EMSA binding reactions were incubated in H2O containing the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) and consisted of 1x binding buffer, 1 μg/μl poly (dl,dC), 2.5% glycerol, 0.05% NP-40, 100 mM KCl, 2.5 mM MgCl2, 1 mM EDTA, 5 μg of protein nuclear extract and 20 fmol of biotin-labelled oligonucleotide (when indicated, 4000 fmol unlabelled oligonucleotide was also added as a competitive negative control). Binding reactions were incubated for 30 minutes at room temperature after which loading buffer was added. Samples were run on a 6% non-denaturing polyacrylamide gel, transferred to a nylon membrane and cross-linked in a UV chamber for 15 minutes. The membrane was developed in X-ray film using the Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) according to the instructions provided by the manufacturer.

Statistical analysis. Statistical analysis was conducted using GraphPad Prism version 6.0 f for Mac OS X (Graphpad Software, California, USA). The results are expressed as mean ± standard error of the mean (SEM). For the analysis of the luciferase activity and the relationship between the different reporter vectors we used a two-tailed paired t-test. Two-way ANOVA was used to compare the differences between the cell lines and the abundance of transcription factors precipitated and evaluated by RT-PCR. Results were considered statistically significant whenever P < 0.05. As a GraphPad software default the values of statistical significance are represented as: P < 0.0001, ****; 0.0001 < P < 0.001, ***; 0.001 < P < 0.01, **; 0.01 < P < 0.05; and P ≥ 0.05 as not significant (NS).
References
1. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Experimental cell research 25, 585–621 (1961).
2. Kim, N. W. et al. Specific association of human telomerase activity with immortalized cells and cancer. Science 266, 194–196 (1994).
3. Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425, doi: 10.1126/science.1207313 (2011).
4. Iao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203, doi: 10.1126/science.1200691 (2011).
5. Lovejoy, C. A. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS genetics 8, e1002772, doi: 10.1371/journal.pgen.1002772 (2012).
6. de Wilde, R. F. et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 25, 1033–1039, doi: 10.1038/modpathol.2012.53 (2012).
7. Iao, Y. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3, 709–722, doi: 10.18632/oncotarget.588 (2012).
8. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959, doi: 10.1126/science.1229259 (2013).
9. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961, doi: 10.1126/science.1230062 (2014).
10. Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nature communications 4, 2185, doi: 10.1038/ncomms13185 (2013).
11. Vinagre, J. et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv: an international journal of pathology 465, 119–133, doi: 10.1007/s00428-014-1608-4 (2014).
12. Melo, M. et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. The Journal of clinical endocrinology and metabolism 99, E754–E765, doi: 10.1210/jc.2013-3734 (2014).
13. Populo, H. et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. The Journal of investigative dermatology 134, 2251–2257, doi: 10.1038/jid.2014.163 (2014).
14. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America 110, 6021–6026, doi: 10.1073/pnas.1303607110 (2013).
15. Campanella, N. C. et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). European journal of human genetics : EJHG 23, 877–879, doi: 10.1038/ejhg.2014.195 (2015).
16. Liu, X. et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer 20, 603–610, doi: 10.1530/ERC-13-0210 (2013).
17. Heidenreich, B., Rachakonda, P. S., Hemminki, K. & Kumar, R. TERT promoter mutations in cancer development. Current opinion in genetics & development 24, 30–37, doi: 10.1016/j.gde.2013.11.005 (2014).
18. Heaphy, C. M. et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. The American journal of pathology 179, 1608–1615, doi: 10.1016/j.ajpath.2011.06.018 (2011).
19. Mathelier, A. et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic acids research 42, D142–D147, doi: 10.1093/nar/gkt499 (2014).
20. Draskovic, I. et al. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proceedings of the National Academy of Sciences of the United States of America 106, 15726–15731, doi: 10.1073/pnas.0907891009 (2009).
21. Brault, M. E. & Autesserre, C. Telomeric recombination induced by dysfunctional telomeres. Mol Biol Cell 22, 179–188, doi: 10.1091/mbc.E10-02-0173 (2011).
22. Yachida, S. et al. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. The American journal of surgical pathology 36, 173–184, doi: 10.1097/PAS.0b013e3182417d56 (2012).
23. Martini, L. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146, 453–460 e455, doi: 10.1053/j.gastro.2013.10.020 (2014).
24. Bell, R. J. et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036–1039, doi: 10.1126/science.aaa0015 (2015).
25. Stern, J. L., Theodosiou, D., Vogelstein, B., Papadopoulos, N. & Cech, T. R. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev 28, 2219–2224, doi: 10.1101/gad.269498.115 (2015).
26. Makowski, M. M. et al. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations. Proteomics 16, 417–426, doi: 10.1002/pmic.201500327 (2016).
27. Maida, Y. et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21, 4071–4079, doi: 10.1038/sj.onc.1205509 (2002).
28. Boora, G. K. et al. Exome level comparison of primary well differentiated neuroendocrine tumors and their cell lines. Cancer Genetics 2015.
29. Rindi, G. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv: an international journal of pathology 449, 395–401, doi: 10.1007/s00428-006-0290-1 (2006).
30. Bosman, F. T., Organization, W. H., Carneiro, F., Cancer, I. A. F. R. O. & Hruban, R. H. WHO Classification of Tumours of the Digestive System. (International Agency for Research on Cancer, 2010).
31. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours. (Wiley, 2011).

Acknowledgements
The authors are grateful to Dr Claudio Sette and Dr Aldo Scarpa who generously shared the cell lines used in this study. The Portuguese Foundation for Science and Technology supported this study through a PhD grant to J.V. (Ref: SFRH/BD/81940/2011). Further funding was obtained from the project “Advancing cancer research: from basic knowledge to application”; NORTE-01-0145-FEDER-000029; “Projetos Estruturados de I&D&I”, funded by Norte 2020 – Programa Operacional Regional do Norte. I3S is an Associate Laboratory of the Portuguese Ministry of Science, Technology and Higher Education that is partially supported by the FCT.

Author Contributions
PS., M.S.S., J.M.L. and M.G. jointly supervised the research. J.V. and P.S. conceived the study. J.V., J.N., R.B., P.G., A.P., M.R., B.M., V.P., J.L. and A.R. performed the experiments. J.P., R.C.O., M.A.C. and J.M.L. provided tumor samples, collected the clinicopathological data and performed the tumor classification. The paper was written with the contribution of all authors.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Vinagre, J. et al. TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Sci. Rep. 6, 29714; doi: 10.1038/srep29714 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/